![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1362876
¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀå ±Ô¸ð, Á¡À¯À² ¹× µ¿Ç⠺м® º¸°í¼ : Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, ºÎ¹®º° ¿¹Ãø(2023-2030³â)U.S. External Counterpulsation Devices Market Size, Share & Trends Analysis Report By Product (Pneumatic ECP Devices, Electrocardiogram (ECG)-Synchronized), By End-use (Hospitals, Cardiac Centers), And Segment Forecasts, 2023 - 2030 |
Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼¿¡ µû¸£¸é ¹Ì±¹ÀÇ Ã¼¿Ü Ä«¿îÅÍÆÞÀü(ECP) ±â±â ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 2¾ï 7,250¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç ¿¹Ãø ±â°£ µ¿¾È 7.6%ÀÇ CAGRÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼ºÀå ¿øµ¿·ÂÀº ½ÉÇ÷°ü ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿äÀ̸ç, ECP Ä¡·á´Â ºñħ½ÀÀû Ư¼º°ú Çù½ÉÁõ ¹× ½ÉºÎÀü µîÀÇ Áúȯ °ü¸®¿¡ ÀÖ¾î ÀÔÁõµÈ È¿°ú·Î ȯÀÚ ¹× ÀÇ·á ¼ºñ½º Á¦°ø¾÷üÀÇ Å« °ü½ÉÀ» ¹Þ°í ÀÖ½À´Ï´Ù.
°ü»óµ¿¸Æ ÁúȯÀÇ À¯º´·ü Áõ°¡, °ü»óµ¿¸Æ ȯÀÚÀÇ Á׻󵿸ưæÈÁõ Áõ°¡, Çù½ÉÁõ ¿¡ÇǼҵåÀÇ ±ÞÁõÀº ¿ÜºÎ ¹Úµ¿ ÀåÄ¡ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Çù½ÉÁõ¿¡ ¼±ÇàÇÏ´Â °ü»óµ¿¸ÆÁúȯ ȯÀÚÀÇ ºñÀ²ÀÌ ³ô°í, Çù½ÉÁõ °ü¸®¸¦ À§ÇÑ ECP ±â±â äÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½ÃÀå ¼ºÀåÀÌ ¿¹»óµÇ¸ç, 40¼¼ À̻󿡼 ³ôÀº Á׻󵿸ưæÈÁõ ¹ß»ý·ü·Î ÀÎÇØ ÀÌ ¿¬·É´ëÀÇ 50%°¡ ½É°¢ÇÑ Á׻󵿸ưæÈÁõÀ¸·Î ¹ßÀüÇÒ ¼ö ÀÖ½À´Ï´Ù. ECP Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.
ü¿Ü Ä«¿îÅÍÆÞ¼¼À̼Ç(ECP) ±â±â ½ÃÀåÀº ¾÷°èÀÇ ±â¼úÀû µµ¾à°ú Çõ½ÅÀ¸·Î ÀÎÇØ Å« ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº °í±Þ ¸ð´ÏÅ͸µ ±â´É, ¸ÂÃãÇü ¿É¼Ç ¹× ÀüÀÚ ÀÇ·á ±â·Ï ½Ã½ºÅÛ ÅëÇÕÀ» Ãß°¡ÇÏ¿© ECP ÀåÄ¡¸¦ Áö¼ÓÀûÀ¸·Î °ÈÇÏ¿© ȯÀÚ °ü¸®, ¾ÈÀü¼º ¹× Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. Àû±ØÀûÀÎ »óȯ Á¤Ã¥ ¹× ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©´Â Ŭ¸®´Ð°ú º´¿ø¿¡¼ ECP ÀåºñÀÇ »ç¿ëÀ» ÃËÁøÇÏ¿© ½ÃÀåÀÇ »ó½Â¼¼¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½ÃÀå ³» ¸¹Àº °æÀï¾÷ü¿Í ÀϺΠ½ÉÀå Áúȯ Ä¡·á¿¡ ´ëÇÑ FDAÀÇ ½ÂÀÎÀº ¼¼°è ECP ±â±â ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.
The U.S. external counterpulsation (ECP) devices market size is expected to reach USD 272.5 million by 2030, growing at a CAGR of 7.6% during the forecast period, according to a new report by Grand View Research, Inc.. The growth is driven by the increasing prevalence of cardiovascular diseases and the demand for effective treatments. ECP therapy, known for its non-invasive nature and proven efficacy in managing conditions like angina pectoris and heart failure, has garnered significant interest from patients and healthcare providers.
The rise in the prevalence of coronary artery diseases, increase in atherosclerosis in coronary artery patients, and surge in angina episodes are projected to drive the external counterpulsation devices market's growth. With a significant proportion of coronary artery disease cases preceding angina and the rising adoption of ECP devices for managing angina, the market is expected to grow. The incidence of atherosclerosis, most common in patients above 40, further contributes to the demand for ECP therapy, as nearly 50% of individuals in this age group are likely to develop serious atherosclerosis conditions.
Significant growth has been seen in the market for external counterpulsation (ECP) devices, driven by technological breakthroughs and innovations in the industry. By adding advanced monitoring capabilities, customization choices, and electronic medical record system integration, manufacturers continuously enhance ECP devices, improving patient care, safety, and treatment outcomes. Positive reimbursement policies and regulatory frameworks promote the growing use of ECP devices in clinic and hospital settings, which adds to the market's upward trend. Additionally, significant competitors in the market and FDA clearance for treating several cardiac diseases are anticipated to fuel the expansion of the worldwide ECP devices market.